These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 6102792)

  • 21. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia.
    McGrath JJ; Soares KV
    Cochrane Database Syst Rev; 2000; (2):CD000459. PubMed ID: 10796546
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Approaches to the problem of preventing hazards of long-term neuroleptic treatment and of avoiding unnecessary drugs.
    Kristjansen P
    Adv Biochem Psychopharmacol; 1980; 24():505-11. PubMed ID: 6105796
    [No Abstract]   [Full Text] [Related]  

  • 23. Changes in plasma homovanillic acid concentrations in schizophrenic patients following neuroleptic discontinuation.
    Davidson M; Kahn RS; Powchik P; Warne P; Losonczy MF; Kaminsky R; Apter S; Jaff S; Davis KL
    Arch Gen Psychiatry; 1991 Jan; 48(1):73-6. PubMed ID: 1670618
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neurochemical studies on tardive dyskinesia. I. Urinary homovanillic acid and plasma prolactin.
    Tripodianakis J; Markianos M; Garelis E
    Biol Psychiatry; 1983 Mar; 18(3):337-45. PubMed ID: 6132625
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tardive dyskinesia in schizophrenic outpatients: prevalence and significant variables.
    Ezrin-Waters C; Seeman MV; Seeman P
    J Clin Psychiatry; 1981 Jan; 42(1):16-22. PubMed ID: 6109715
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neuroleptic-induced supersensitivity psychosis.
    Chouinard G; Jones BD; Annable L
    Am J Psychiatry; 1978 Nov; 135(11):1409-10. PubMed ID: 30291
    [No Abstract]   [Full Text] [Related]  

  • 27. Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia.
    Tsai G; Goff DC; Chang RW; Flood J; Baer L; Coyle JT
    Am J Psychiatry; 1998 Sep; 155(9):1207-13. PubMed ID: 9734544
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of neuroleptic reduction in schizophrenic outpatients receiving high doses.
    Leblanc G; Cormier H; Gagné MA; Vaillancourt S
    Can J Psychiatry; 1994 May; 39(4):223-9. PubMed ID: 7913872
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics.
    Chouinard G; Jones BD
    Am J Psychiatry; 1980 Jan; 137(1):16-21. PubMed ID: 6101522
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High plasma clozapine levels in tardive dyskinesia.
    Pollack S; Lieberman J; Kleiner D; Szymanski S; Kane J; Borenstein M; Cooper T
    Psychopharmacol Bull; 1993; 29(2):257-62. PubMed ID: 8290674
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tardive dyskinesia and glucid metabolism.
    Brousse G; Meary A; Mouret J; Blanc O; Hueber T; Lemoine P; Llorca PM; Lachaux B
    Hum Psychopharmacol; 2007 Aug; 22(6):373-80. PubMed ID: 17579925
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Nithsdale schizophrenia surveys. IX: Akathisia, parkinsonism, tardive dyskinesia and plasma neuroleptic levels.
    McCreadie RG; Robertson LJ; Wiles DH
    Br J Psychiatry; 1992 Jun; 160():793-9. PubMed ID: 1352165
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of tardive dyskinesia with bromocriptine. A test of the receptor modification strategy.
    Lieberman JA; Alvir J; Mukherjee S; Kane JM
    Arch Gen Psychiatry; 1989 Oct; 46(10):908-13. PubMed ID: 2572205
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevention and management of tardive dyskinesia.
    Jeste DV; Wyatt RJ
    J Clin Psychiatry; 1985 Apr; 46(4 Pt 2):14-8. PubMed ID: 2858473
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neuroendocrine effects of apomorphine in chronic schizophrenic patients under long-term neuroleptic therapy and after drug withdrawal: relations to psychopathology and tardive dyskinesia.
    Müller-Spahn F; Ackenheil M; Albus M; May G; Naber D; Welter D; Zander K
    Psychopharmacology (Berl); 1984; 84(3):436-40. PubMed ID: 6151210
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of the branched-chain amino acids in the treatment of tardive dyskinesia in men.
    Richardson MA; Bevans ML; Read LL; Chao HM; Clelland JD; Suckow RF; Maher TJ; Citrome L
    Am J Psychiatry; 2003 Jun; 160(6):1117-24. PubMed ID: 12777270
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of neuroleptic adjustment on clinical condition and tardive dyskinesia in schizophrenic patients.
    Branchey MH; Branchey LB; Richardson MA
    Am J Psychiatry; 1981 May; 138(5):608-12. PubMed ID: 7015884
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum neuroleptic concentrations and tardive dyskinesia.
    Jeste DV; Linnoila M; Wagner RL; Wyatt RJ
    Psychopharmacology (Berl); 1982; 76(4):377-80. PubMed ID: 6126895
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tardive dyskinesia and the behavioral consequences of chronic neuroleptic treatment.
    Gualtieri CT; Guimond M
    Dev Med Child Neurol; 1981 Apr; 23(2):255-9. PubMed ID: 6111511
    [No Abstract]   [Full Text] [Related]  

  • 40. Use of the selective serotonin 3 receptor antagonist ondansetron in the treatment of neuroleptic-induced tardive dyskinesia.
    Sirota P; Mosheva T; Shabtay H; Giladi N; Korczyn AD
    Am J Psychiatry; 2000 Feb; 157(2):287-9. PubMed ID: 10671405
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.